抗CD47在肿瘤免疫治疗中研究进展

Advances of anti-CD47 in tumor immunotherapy

CD47作为先天性免疫检查点分子,在多种恶性肿瘤中高表达,参与肿瘤发生、发展。CD47作为肿瘤免疫治疗靶点已成为近年研究热点。抗CD47单克隆抗体(Hu5F9-G4、CC-90002)、重组融合蛋白(ALX-148、TTI-621)、双靶向抗体(IAB、IMM0306)等抗CD47药物治疗血液肿瘤及实体肿瘤疗效良好。本文就抗CD47在肿瘤免疫治疗中的研究进展作一综述。

As a natural immune checkpoint molecule,CD47 is highly expressed in almost all malignant tumors,and participates in the occurrence and development of tumors.Being a target for cancer therapy,CD47 has drawn much attention in recent years.Anti-CD47 antibodies(Hu5F9-G4,CC-90002),decoy receptor fusion protein(ALX-148,TTI-621)and bispecific antibodies(IAB,IMM0306)have encouraging efficacies on solid tumors and hematological malignancies.This paper reviews the research progress of application of anti-CD47 in tumor immunotherapy.